Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Recombinetics Inc. is a leading biotechnology company specializing in the development and application of precision gene-editing technologies. Their primary focus is on improving animal health, welfare, and productivity in agriculture (via subsidiary Acceligen) and developing gene-edited animal models for biomedical research and human therapeutic applications (via subsidiary Makana). They leverage advanced genetic tools like TALENs and CRISPR/Cas9 to create animals with desirable traits, such as disease resistance, enhanced productivity, and reduced environmental impact, as well as human-compatible organs for transplantation.
The St. Paul headquarters serves as the central hub for Recombinetics' strategic leadership, core research and development activities, intellectual property management, business development, and administrative operations.
Likely equipped with state-of-the-art laboratories for molecular biology, genetics, and embryology, along with bioinformatics capabilities. Its location provides proximity to the University of Minnesota and other research institutions.
The work culture at Recombinetics is characterized by scientific innovation, collaboration, and a strong ethical focus. Employees are typically driven by the potential of gene editing to solve significant global challenges in food production and human health.
The headquarters' location in Minnesota allows Recombinetics to tap into a rich ecosystem of agricultural expertise, veterinary science, and biomedical talent, fostering collaborations and innovation.
Recombinetics Inc. establishes its global presence primarily through its subsidiaries (Acceligen for agriculture, Makana for human therapeutics), strategic partnerships, collaborations with international research institutions, and licensing of its gene-editing technologies. They target key agricultural markets worldwide and engage with the global biomedical community to advance their human health initiatives.
1295 Northland Dr, Suite 250
St. Paul
Minnesota
USA
Address: Specific address not publicly listed, operates via Acceligen (subsidiary)
To implement and commercialize precision breeding technologies in South American livestock markets, adapting solutions to local agricultural needs and regulatory environments.
Address: Specific address related to Makana Therapeutics (subsidiary)
To advance the science and application of xenotransplantation, providing a dedicated facility for raising and studying genetically engineered pigs for organ transplantation into humans.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Recombinetics Inc.' leadership includes:
Recombinetics Inc. has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major, widely reported C-suite executive hires or exits at Recombinetics Inc. in the last 12 months. The core leadership team appears to have remained stable.
Discover the tools Recombinetics Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Recombinetics Inc. likely utilizes common corporate email formats. The most probable format is the first initial followed by the last name, or first name followed by last name, at their domain.
[first_initial][last]@recombinetics.com
Format
mwalton@recombinetics.com
Example
80%
Success rate
FDA • May 17, 2024
The FDA announced a low-risk determination for marketing products, including food, from two genome-edited beef cattle and their offspring after determining the product is safe to eat. These PRLR-SLICK cattle, developed by Recombinetics' subsidiary Acceligen, are engineered to have slick coats, helping them better withstand hot weather, which can improve animal welfare and productivity....more
Recombinetics Press Release / Business Wire • September 14, 2023
Recombinetics announced its acquisition of Makana Therapeutics, Inc., a company focused on developing genetically engineered pigs with organs suitable for human transplantation. This acquisition significantly expands Recombinetics' capabilities in the biomedical field....more
Successful Farming • March 21, 2022
Recombinetics' subsidiary, Acceligen, has developed pigs genetically edited for resistance to Porcine Reproductive and Respiratory Syndrome (PRRS), a costly disease in the swine industry. The company is advancing towards commercialization....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Recombinetics Inc., are just a search away.